Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

Pemvidutide (ALT-801) iconPemvidutide (ALT-801)Small moleculeNo amino acid sequence. Icon reflects category theme only.

Pemvidutide (ALT-801) Dosage Calculator

Weight Loss · Phase 2 · Grade C · ~4-6 days half-life (estimated) · Injection

Dosing protocol

Pemvidutide (ALT-801) Dosage

LevelDose / InjectionFrequency
Beginner1.2 mgWeekly
Moderate1.8 mgWeekly
Aggressive2.4 mgWeekly

Cycle: No scheduled off period.

No syringe calculation for this route

Subcutaneous

Pemvidutide (ALT-801) has no default water volume for this calculator, so there are no syringe units to calculate here. Dosing runs 1.2 mg to 2.4 mg per administration, weekly.

If your product does arrive as a powder, use the universal reconstitution calculator and enter your own vial size and water volume.

Open Pemvidutide (ALT-801) details
Side effects, protocols by goal, storage, and the sources behind these dosing numbers.

About Pemvidutide (ALT-801)

Beginner, moderate, and aggressive dosing amounts with timing. Free to use.

Pemvidutide (ALT-801) combines GLP-1 and glucagon receptor activation in a single weekly injection. Phase 2 data: 15.6% weight loss plus up to 76% liver fat reduction. FDA Breakthrough Therapy Designation for MASH granted January 2026. Currently, clinical trial access only.

GLP-1 AgonistGlucagon AgonistDual AgonistWeight ManagementLiver Fat ReductionMASH/NASH
Subcutaneous. Typical beginner frequency: weekly.
Store at 2-8°C (36-46°F). Refrigerate at 2-8°C.

View side effects and safety warnings →

Quick-Start: How to Use Pemvidutide (ALT-801)

  1. 1Inject subcutaneously once weekly into the abdomen, thigh, or upper arm. Pick the same day each week and rotate injection sites.
  2. 2Use a 29-31 gauge insulin syringe (0.5 mL or 1 mL). If reconstituting research-grade material: 5 mg vial plus 2 mL bacteriostatic water gives 2.5 mg/mL. For 1.2 mg, draw to 48 units. For 1.8 mg, draw to 72 units. For 2.4 mg, draw to 96 units. With a 10 mg vial plus 2 mL, those same doses are 24, 36, and 48 units.
  3. 3Clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45-90 degree angle. Inject slowly.
Full usage guide →

Pemvidutide (ALT-801) Dosing Protocol

Clinical TrialMOMENTUM Phase 2 trial: pemvidutide for 48 weeks in adults with obesity (NCT05295875)
LevelDose / InjectionFrequency
Beginner1.2 mgWeekly
Moderate1.8 mgWeekly
Aggressive2.4 mgWeekly
Note:

Pemvidutide isn't available from any consumer or grey-market source. The EuPort lipidated/albumin-conjugated structure can't be synthesized for the research-grade market. Any research-grade product claiming to be pemvidutide is mislabeled or outright fraudulent.

In clinical trials, pre-filled pens were used, so reconstitution wasn't part of the protocol. Research-grade lyophilized material exists only as a lab reagent for preclinical use. For reference, a 5 mg vial plus 2 mL bacteriostatic water gives 2.5 mg/mL. At that concentration, 1.2 mg equals 48 units on a U-100 insulin syringe, 1.8 mg equals 72 units, and 2.4 mg equals 96 units. A 10 mg vial plus 2 mL gives 5 mg/mL, so the same doses become 24, 36, and 48 units respectively.

The non-obvious point: no dose titration was mandated in MOMENTUM. But starting at 1.2 mg for four weeks before escalation is practical given the 52% nausea rate at the top dose. The 2.4 mg arm in MOMENTUM actually did use a four-week 1.2 mg lead-in.

Dosing based on MOMENTUM Phase 2 trial: pemvidutide for 48 weeks in adults with obesity (NCT05295875): 8 published references.View all sources →

Ask AI about this math

Cross-check your Pemvidutide (ALT-801) reconstitution math with AI

Pemvidutide (ALT-801) Cost

Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →

Pemvidutide (ALT-801) Pharmacokinetics

Pharmacokinetics: Active Dose Over Time

t½ = ~4-6 days (estimated)
50%25%12.5%100%75%50%25%0%05d10d15d20d25dTime after injectionDose remaining
After 1 half-life (5d): 50% remainsAfter 2 half-lives (10d): 25% remainsAfter 3 half-lives (15d): 12.5% remains
At a 1.8 mg dose: 50% = 0.9 mg remaining after 5d. Moderate-tier frequency in our sources: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Read the full Pemvidutide (ALT-801) guide →

Related Tools

Frequently Asked Questions

Store Pemvidutide (ALT-801) at 2-8°C (36-46°F). Refrigerate at 2-8°C.